Medical Versus Surgical Treatment of Incomplete First Trimestric Abortion


  • Aseel Mosa Jabber


Pregnancy, Misoprostol, Abortion in Nassiriyah


Objective: to assess efficacy and risks of medical treatment of incomplete abortion using misoprostol versus surgical procedures.

Methods:  A prospective comparative study included 208 women with incomplete abortion with gestational age between 5th and 12th week randomized equally to two groups Group I received 600 micro gram misoprostol  as single oral dose and Group II underwent surgical dilatation and evacuation. Primary outcome was successful treatment all women give a written acceptance of being involved in the trial.

Results:  There was no statistically significant difference between Misoprostol and surgical groups regarding endometrial thickness evaluated after treatment (10.5±2.65 versus. 9.3±1.97 respectively, where P value 0.251Non significant , treatment failure (11 versus. 6 respectively, where P value 0.071 Non significant), those with blood loss more than 500 cc ( 1 versus. 3 respectively, where P value 0.482 Non significant ) and those who needed recurrettage ((11 versus. 6 respectively, where value 0.064 Non significant). Side effects of treatment showed no statistically significant difference between the studied women (fever occurred in 3 versus. 1, IUS in 0 versus. 1 and vomiting occurred in 1 versus. 3 in medical versus. surgical women respectively ,where P value > 0.05)  except diarrhea which was much more common in women under Misoprostol treatment (28 versus. 0 respectively, where value < 0.001).                                                                  

Conclusion:  Medical treatment is effective and acceptable and less costly than surgical treatment in women with incomplete abortion.


Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Rouse DJ and Sponge CY. Abortion . In: Cunningham FG, Williams JW, editors. William's obstetrics. 24th ed. New York (NY): McGraw-Hill; 2014. Chapter 18p. 350-376.

Simpson JL, Jauniaux ERM: Pregnancy loss. In: Gabbe SG, Niebyl JR, Simpson JL, eds. Obstetrics: Normal and Problem Pregnancies. 5th ed. Philadelphia, Pa: Elsevier Churchill Livingstone; chap 24, 2007

Little AB. There’s many a slip ‘twixt implantation and the crib. N Engl J Med;2008; 319: 241–242.

Wilcox AF, Weinberg CR, O’Connor JF, et al: Incidence of early loss of pregnancy. N Engl J Med 319:189, 1988

Giacomucci E, Bulletti C, Polli V. Immunologically mediated abortion (IMA). J Steroid Biochem Mol Biol, 2008: 49: 107–121.

Luise C, Jermy K, May C, et al: Outcome of expectant management of spontaneous first trimester miscarriage: observational study. BMJ 324:873, 2002

Kollitz K, Meyn, Lohr P, Creinin M: Mifepristone and misoprostol for early pregnancy failure: a cohort analysis. Am J Obstet Gynecol 204:386.e1–6, 2011

Neilson JP, Gyte GM, Hickey M, et al: Medical treatments for incomplete miscarriage (less than 24 weeks). Cochrane Database Syst Rev 1:CD007223, 2010

Creinin MD, Huang X, Westhoff C: et al: Factors related to successful misoprostol treatment for early pregnancy failure. Obstet Gynecol 107:901, 2006

Smith LF, Ewings PD, Guinlan C: Incidence of pregnancy after expectant, medical, or surgical management of spontaneous first trimester miscarriage: long term follow-up of miscarriage treatment (MIST) randomized controlled trial. BMJ 339:b3827, 2009

Zhang J, Gilles J, Barnhart K, Creinin M, Westhoff C, Frederick M (2005): Drug Offers Alternative to Surgical Treatment After Miscarriage. New England Journal of Medicine.

Henshaw R, Cooper K, el-Refaey H . Medical management of miscarriage: non-surgical uterine evacuation of incomplete and inevitable spontaneous abortion. Br Med J;2003; 306: 894–895.

Hughes J, Ryan M, Hinshaw K et al. The costs of treating miscarriage: a comparison of medical and surgical management. Br J Obstet Gynaecol;2006: 103: 1217–1221.

Taylor J, Diop A, Blum J, Dolo O, Winikoff B . Oral misoprostol as an alternative to surgical management for incomplete abortion. Int J Gynaecol obstet;2011: 112 (1): 40- 4.

El-Bradie SM, Elsaid MH, Ragab WS, Elssery KM, Mahmoud M. Endometrial thickness and serum beta-hCG as predictors of the effectiveness of oral misoprostol in early pregnancy failure. J Obstet Gynaecol Can;2008: 30 (10): 877-81.

Rausch M, Lorch S, Chung K, Frederick M, Zhang J, Barnhart K. A cost-effectiveness analysis of surgical versus medical management of early pregnancy loss. Fertil Steril. 2012 ;97(2):355-60.

World Health Organization (WHO) Unsafe abortion: Global and regional estimates of the incidence of unsafe abortion and associated mortality in 2008.6. Geneva: WHO; 2011.

Nanda K1, Peloggia A, Grimes D, Lopez L, Nanda G. Expectant care versus surgical treatment for miscarriage. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003518.

Zhang J, Gilles JM, Barnhart K, Creinin MD, Westhoff C, Frederick MM; National Institute of Child Health Human Development (NICHD) Management of Early Pregnancy Failure Trial. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. N Engl J Med. 2005 Aug 25;353(8):761-9.

Behnamfar F, Mahdian M, Rahimi F, Samimi M. Misoprostol Abortion: Ultrasonography versus Beta-hCG Testing for Verification of Effectiveness. Pak J Med Sci. 2013 Nov;29(6):1367-70.

Neilson JP, Gyte GM, Hickey M, Vazquez JC, Dou L. Medical 226 treatments for incomplete miscarriage (less than 24 weeks). Cochrane Database Syst Rev. 2010(1):CD007223.

Petersen SG, Perkins AR, Gibbons KS, Bertolone JI, Mahomed K. The medical management of missed miscarriage: outcomes from a prospective, single-centre, Australian cohort. Med J Aust. 2013 Sep 2;199(5):341-6.

Kovavisarach E, Jamnansiri C. Intravaginal misoprostol 600 microg and 800 microg for the treatment of early pregnancy failure. Int J Gynaecol Obstet. 2005 Sep;90(3):208-12.

Verschoor MA, Lemmers M, Bossuyt PM, Graziosi GC, Hajenius PJ, Hendriks DJ, van Hooff MA, van Meurs HS, Opmeer BC, van Tulder MW, Bouwma L,Catshoek R, Geomini P, Klinkert ER, Langenveld J, Nieboer TE, van der Ploeg JM, Radder CM, Spinder T, van der Voet LF, Mol BW, Huirne JA, Ankum WM. Surgical versus expectant management in women with an incomplete evacuation of the uterus after treatment with misoprostol for miscarriage: the MisoREST trial. BMC Pregnancy Childbirth. 2013 May 2;13:102.

Blandine T, Ouattara AZ, Coral A, Hassane C, Clotaire H, Dao B, Lankoande J, Diop A, Blum J. Sublingual [corrected] misoprostol as first-line care for incomplete abortion in Burkina Faso. Int J Gynaecol Obstet. 2012 Nov;119(2):166-9.

Fawole AO1, Diop A, Adeyanju AO, Aremu OT, Winikoff B. Misoprostol as first-line treatment for incomplete abortion at a secondary-level health facility in Nigeria. Int J Gynaecol Obstet. 2012 Nov;119(2):170-3.

Ngoc NT, Shochet T, Blum J, Hai PT, Dung DL, Nhan TT, Winikoff B. Results from a study using misoprostol for management of incomplete abortion in Vietnamese hospitals: implications for task shifting. BMC Pregnancy Childbirth. 2013 May 22;13:118.

Hooker AB, Lemmers M, Thurkow AL, Heymans MW, Opmeer BC, Brölmann HA, Mol BW, Huirne JA. Systematic review and meta-analysis of intrauterine adhesions after miscarriage: prevalence, risk factors and long-term reproductive outcome. Hum Reprod Update. 2014 Mar-Apr;20(2):262-78.

Lemmers M, Verschoor MA, Hooker AB, Opmeer BC, Limpens J, Huirne JA, Ankum WM, Mol BW. Dilatation and curettage increases the risk of subsequent preterm birth: a systematic review and meta-analysis. Hum Reprod. 2016 Jan;31(1):34-45.

Lemmers M, Verschoor MA, Oude Rengerink K, Naaktgeboren C, Opmeer BC, Bossuyt PM, Huirne JA, Janssen CA, Radder C, Klinkert ER, Langenveld J, Catshoek R, Van der Voet L, Siemens F, Geomini P, Van Hooff MH, Van der Ploeg JM, Coppus SF, Ankum WM, Mol BW. MisoREST study group. MisoREST: surgical versus expectant management in women with an incomplete evacuation of the uterus after misoprostol treatment for miscarriage: a randomized controlled trial. Hum Reprod. 2016 Sep 2. [Epub ahead of print]